Get access

Bevacizumab: not as good with more adverse reactions?

Authors


  • Conflict/competing interest: The author is a member of the Novartis International Advisory Board and the Australian Advisory Board and has received payment for giving lectures both in Australia and overseas.

No abstract is available for this article.

Ancillary